Low vitamin D is consistently associated with higher dementia risk in observational studies. When that association was tested in randomized trials, it did not hold: the VitaMIND trial (2025) supplemented adults with mild-to-moderate deficiency and found no significant cognitive benefit, and the Finnish Vitamin D Trial found no reduction in diagnosed dementia among healthy older adults taking D3. Correcting a genuine deficiency is worth doing for bone and muscle health. It is not an established way to protect thinking or memory.
Neuro-Thrive publishes a full dose panel rather than a proprietary blend: vitamin D3 20 mcg, bacopa monnieri 300 mg standardized to 50% bacosides, alpha-GPC 150 mg, GABA 100 mg, PQQ 10 mg, plus niacin and B6. Two things you should know before buying it. Its PQQ is 10 mg, where the cognitive trial the category is marketed on used 20 mg/day. And it contains alpha-GPC, which a large South Korean cohort associated with roughly 43% higher 10-year stroke risk — observational, confounded by indication, but large and dose-dependent enough that anyone with cardiovascular history should raise it with a clinician. Its 20 mcg of D3 is a maintenance amount, not a deficiency-correction dose.
We earn a commission if you buy through this link. It costs you nothing extra and it does not change what we write.
Full Neuro-Thrive review: doses, price, guarantee →
Check the current price →What vitamin D is, and what “deficiency” means
Vitamin D is a fat-soluble hormone precursor. Skin makes cholecalciferol (D3) from UVB exposure; food and supplements provide D3 or ergocalciferol (D2). The liver converts it to 25-hydroxyvitamin D — 25(OH)D — which is the form measured in blood and the number your doctor is looking at.4
Vitamin D receptors are present throughout the brain, and the vitamin participates in calcium signaling, immune regulation and neurotrophic pathways. That is a mechanism, not an effect. Mechanistic plausibility is where almost every failed supplement in this field started, which is why we separate the two on every page. Our evidence rating method explains how.
The evidence, by study type
The observational literature and the randomized literature point in opposite directions, and the gap between them is the entire story of this ingredient.
Observational. A 2025 dose-response meta-analysis of observational studies found low 25(OH)D associated with elevated dementia risk, with a graded relationship — lower levels, higher risk.3 That is a consistent and repeatedly reproduced finding, and it is why vitamin D appears in so many brain formulas.
Randomized. The trials are null. VitaMIND (2025) supplemented adults who had mild-to-moderate vitamin D deficiency and reported no significant cognitive benefit.1 The Finnish Vitamin D Trial gave D3 to healthy older adults and found no reduction in the incidence of diagnosed dementia.2 VITAL and other large trials likewise found no cognitive benefit.4
| Study | Population | Design | Cognitive result |
|---|---|---|---|
| VitaMIND (2025) | Adults with mild-to-moderate deficiency | RCT, D vs placebo | No significant benefit |
| Finnish Vitamin D Trial | Healthy older adults | RCT, D3 vs placebo | No drop in diagnosed dementia |
| VITAL and other large trials | Older adults | RCT | No cognitive benefit |
| 2025 dose-response meta-analysis | Observational cohorts | Pooled cohort data | Low 25(OH)D linked to higher dementia risk |
Trials in this area have used roughly 400–4,000 IU/day, with 2,000 IU/day a common choice.4 Nobody has shown that a higher dose rescues the null result, and the tolerable upper intake level for adults is 4,000 IU/day, so there is not much headroom to test.
Correcting a deficiency and supplementing someone replete are two different interventions
This distinction gets collapsed in marketing, and collapsing it is how a null result gets sold as a benefit. They are not the same experiment.
Deficiency correction means taking someone whose 25(OH)D is genuinely low and raising it into the normal range. VitaMIND tested exactly this — adults with mild-to-moderate deficiency — and found no significant cognitive benefit.1 That is the more surprising of the two null results, because it is the intervention with the best theoretical case.
Supplementing the replete means adding vitamin D to people whose levels are already adequate. The Finnish Vitamin D Trial recruited healthy older adults, not a deficient population, and found no reduction in diagnosed dementia.2 Nothing in that design was set up to detect a deficiency-correction effect, and it did not claim to.
The reason this matters is that other nutrients behave very differently across the same divide. Vitamin B12 is the clean example: correcting a genuine B12 deficiency can reverse real cognitive symptoms, while giving B12 to replete people does nothing for cognition.9 Vitamin D was expected to follow that pattern. On the cognitive endpoint, so far, it has not.
Why the observational signal is probably not causal
The most likely explanation is reverse causation plus confounding, and it is not a subtle argument. People who are frail, housebound, chronically ill or already declining cognitively go outside less. Going outside less means less UVB exposure, which means lower 25(OH)D. The low vitamin D is downstream of the poor health, not upstream of it.
Sunlight exposure also tracks with physical activity, social contact, general mobility and diet quality — all of which have their own relationships with cognitive aging. Observational studies adjust for what they can measure, and residual confounding survives that adjustment routinely.
This is not a vitamin D-specific problem. Omega-3 followed the same arc: cohorts linking high fish intake to substantially lower dementia risk, then randomized trials at 500–2,000 mg/day of EPA and DHA that found no cognitive improvement in healthy older adults or in established Alzheimer’s disease.8 When a strong observational association meets a well-run trial and loses, the trial is usually right.
Dosing at a glance
- RDA: 600 IU (15 mcg) per day up to age 70; 800 IU (20 mcg) after 70.4
- Typical deficiency correction: 1,000–4,000 IU/day, under clinician supervision, with follow-up bloodwork.
- Tolerable upper intake level: 4,000 IU/day for adults.4
- Used in cognitive trials: 400–4,000 IU/day. None of it worked for cognition.
The practical point: you do not dose vitamin D for your brain. You dose it against a blood test, for bone and muscle endpoints where the evidence is much better, and you stop guessing.
Safety and interactions
Vitamin D is safe at ordinary doses and genuinely not safe at extraordinary ones. The problem at chronic high intake is hypercalcemia — too much calcium in the blood — which presents as nausea, kidney stones, vascular calcification and, in a bitter irony for a cognitive supplement, confusion.4
⚠️ Talk to your prescriber first
Hypercalcemia risk at chronic doses above 10,000 IU/day. Thiazide diuretics add to that risk. Digoxin is the serious one — hypercalcemia potentiates digoxin toxicity and arrhythmia. Corticosteroids reduce vitamin D metabolism and calcium absorption. Orlistat and cholestyramine reduce absorption. Statins may interact via CYP3A4. And in sarcoidosis, primary hyperparathyroidism or other granulomatous disease, hypercalcemia can occur at doses most people tolerate fine.4
If you are taking a combination brain formula, check the total. Stacking a multivitamin, a D3 capsule and a nootropic blend that also contains D3 is how people quietly pass the upper limit. The same arithmetic applies to vitamin B6, where the consequence of accumulation is neuropathy rather than hypercalcemia.
How it’s sold
Vitamin D appears on brain supplement labels for three reasons, none of which is a randomized cognitive trial. It is cheap. It has a real, publishable observational literature that can be cited without technically lying. And it is a vitamin, which carries a safety halo that a nine-botanical blend does not.
The usual sales sentence is some version of “studies link low vitamin D to cognitive decline.” That sentence is true. It is also the exact sentence that the randomized trials were designed to test, and did not support. Watch for the pivot from association to instruction — from “linked to” straight to “so take this.”
Doses on labels are usually modest, in the 400–2,000 IU range, which is sensible from a safety standpoint and irrelevant from a cognitive one. If a formula’s headline argument rests on vitamin D, that tells you something about the rest of the formula. Our list of ingredients that signal a bad brain supplement covers the harder cases.
Our verdict
Evidence tier for cognition: Weak — and arguably negative, since this is a compound that has been properly tested and did not deliver.
Get your 25(OH)D checked if you have reason to think it is low: limited sun exposure, darker skin at high latitude, malabsorption, older age, or a clinician who suggests it. If it is low, correct it, because deficiency has real consequences for bone and muscle. Do not expect your thinking to change, and do not buy a brain formula for its vitamin D content.
If you want the intervention in this category with the best randomized evidence behind it, it is unglamorous: a plain daily multivitamin-mineral, which in COSMOS improved global cognition and memory in adults over 65 across three sub-studies.56 We compare that directly against a stack in multivitamin vs nootropic stack.
What would change our mind
A randomized trial that enrolls only adults with genuinely low 25(OH)D — not mild insufficiency, but the bottom of the distribution — corrects them into the normal range, runs for at least three years, and uses a pre-registered cognitive primary endpoint. VitaMIND is the closest existing attempt and it was null in mild-to-moderate deficiency. A trial in severe deficiency, adequately powered, is the study that has not been done, and it is the one that would move this page.
Frequently asked questions
Does vitamin D deficiency cause brain fog?
Deficiency is associated with fatigue and low mood, which people often describe as brain fog. But the randomized evidence that correcting it improves cognitive test performance is absent — VitaMIND supplemented deficient adults and found no significant cognitive benefit. If your bloodwork is normal and the fog persists, this page covers what else to look at.
How much vitamin D should I take for memory?
There is no dose for memory, because no dose has been shown to help memory. Trials used 400–4,000 IU/day and found nothing on cognitive endpoints. Dose against a blood test and your clinician’s advice instead.
Is 5,000 IU a day safe?
It is above the tolerable upper intake level of 4,000 IU/day for adults, which is a threshold for routine unsupervised use rather than a cliff edge. Short courses at higher doses are prescribed for documented deficiency. Chronic self-dosing above 10,000 IU/day is where hypercalcemia becomes a real concern. This is a conversation for your doctor, not a supplement label.
Why do observational studies and trials disagree about vitamin D?
Because low vitamin D is a marker of being unwell rather than a cause of it. Frailty, illness and cognitive decline all reduce time spent outdoors, which lowers 25(OH)D. The observational studies pick up that relationship and cannot tell you which direction it runs. Randomization can, and it says the arrow does not point the way the marketing implies.
Related reading
- Do nootropics actually work? An honest tier list
- A daily multivitamin vs a nootropic stack
- The case against brain supplements
- Vitamin B6 toxicity: the neuropathy nobody reads the label for
- Exercise and memory: the strongest intervention nobody sells
- Brain fog when your bloodwork comes back normal
Sources
- VitaMIND randomized controlled trial, JAMDA (2025)
- Finnish Vitamin D Trial (FIND) — dementia incidence
- Dose-response meta-analysis of observational studies, Frontiers in Neurology (2025)
- NIH Office of Dietary Supplements — Vitamin D fact sheet for health professionals
- COSMOS-Mind, Alzheimer’s & Dementia
- COSMOS-Clinic and meta-analysis of the three COSMOS cognitive studies, AJCN
- COSMOS trial — published results
- NIH Office of Dietary Supplements — Omega-3 fatty acids fact sheet
- NIH Office of Dietary Supplements — Vitamin B12 fact sheet
- Association of L-alpha-glycerylphosphorylcholine with subsequent stroke risk — Korean national cohort
- Nakano et al., pyrroloquinoline quinone disodium salt and brain function, Food & Function (2023)
These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.
This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.